EHEllen J. Hoekman

Ellen J. Hoekman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ellen J. Hoekman has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Carina G. J. M. Hilders

    Department of Gynecology, Reinier de Graaf Hospital, Delft, the Netherlands

    2 shared publications
  • Cornelis D. de Kroon

    Department of Gynecology and IVF, Leiden University Medical Center, Leiden, The Netherlands

    2 shared publications
  • Frank W. Jansen

    Leiden University Medical Center, Department of Gynecology, Leiden, South Holland, the Netherlands

    2 shared publications
  • Leoni A. Louwe

    Department of Gynecology and IVF, Leiden University Medical Center, Leiden, The Netherlands

    2 shared publications
  • Alexander A. W. Peters

    Department of gynecology, Leiden University Medical Center, P/O Box 9600, 2300RC, Leiden, The Netherlands

    1 shared publication
  • C. A. M. Jansen

    IVF Dept., Reinier de Graaf Group, P/O Box 998, 2275 CX Voorburg, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Ovarian tissue cryopreservation: Low usage rates and high live‐birth rate after transplantation

    by Ellen J. Hoekman, Leoni A. Louwe, Maxime Rooijers, Lucette A. J. van der Westerlaken, Nicole F. Klijn, Gonneke S. K. Pilgram, Cornelis D. de Kroon, Carina G. J. M. Hilders

    Introduction: The likelihood of survival after cancer treatment among young women with cancer has increased considerably, quality of life after treatment has drawn more attention. However, in young fertile women, fertility preservation is an important issue with regard to quality of life. One of the options of fertility preservation is ovarian tissue cryopreservation. The purpose of this follow‐up study is to present our clinical experiences and evaluate the long‐term follow up of ovarian cryopreservation to improve future patient selection.Material and methods: From July 2002 to December 2015 at the Leiden University Hospital, the Netherlands, 69 young women underwent ovarian tissue cryopreservation when they were at risk of iatrogenic premature ovarian insufficiency. Follow‐up data with regard to ovarian function were obtained until October 2018, from medical records and questionnaires.Results: Of the 69 women in whom ovarian tissue cryopreservation was performed, 12 died (15.9%), 57 were approached to participate, of which 6 were lost to follow up. The indications for ovarian tissue cryopreservation were malignant (81.1%) and benign (18.9%) diseases in which gonadotoxic treatment was scheduled. In total, twenty women (39.2%) are known to have premature ovarian insufficiency due to gonadotoxic treatment. Fifteen women conceived spontaneously, and delivered 25 babies. In this cohort, the usage rate of autotransplantation is 8.7% (7/69). In total, nine autotransplantations of cryopreserved ovarian tissue were performed in seven patients (of which 1 ovarian tissue cryopreservation was performed in another hospital) after which 6 babies were born to four women, giving a live‐birth rate of 57%.Conclusions: Ovarian tissue cryopreservation followed by autotransplantation is an effective method to restore fertility (live‐birth rate of 57%). The usage rate of 8.7% (6/69) indicates that more knowledge about the risk of premature ovarian insufficiency after gonadotoxic treatment is needed to be able to offer ovarian tissue cryopreservation more selectively.


  • Ovarian function after ovarian transposition and additional pelvic radiotherapy: A systematic review

    by Ellen J. Hoekman, Emily A.B.J. Broeders, Leoni A. Louwe, Remi.A. Nout, Frank W. Jansen, Cornelis.D. de Kroon


  • Open Access

    Ovarian survival after pelvic radiation: transposition until the age of 35 years

    by Ellen J. Hoekman, Dan Knoester, Alexander A. W. Peters, Frank W. Jansen, Cornelis D. de Kroon, Carina G. J. M. Hilders

    Purpose To evaluate the effectiveness of ovarian transposition (OT) prior to radiation therapy (RT) and to evaluate the effect of age on ovarian survival (OS) after OT. Methods We performed a retrospective control study, with women (aged < 45 years) who underwent OT prior to pelvic radiation, versus women diagnosed with cervical cancer and treated with hysterectomy/trachelectomy and radiation therapy. All women were treated between 1989 and 2010. The 5 years OS rate was calculated, with a sub-analysis for age (25–30; 31–35 and 36–40 years). Ovarian failure was defined as climacteric complaints (with or without starting hormone replacement therapy) and/or laboratory measurements (FSH > 40 IU/L and/or estradiol < 100 pmol/L), or bilateral salpingo oophorectomy. Women were censored at recurrence. Results Twenty-seven women after OT and 29 controls were included. The radiation dose was 44.8 Gy (25.0–63.0 Gy) and 46.3 Gy (45.0–50.0 Gy), respectively. The 5-year ovarian survival rate was 60.3% versus controls 0% (p < 0.001 95% CI 3.48–11.50). Despite the decrease in ovarian survival after OT with increasing age, in all age groups (25–30, 30–35 and 35–40) ovarian survival after OT was significantly better compared to women without OT (p = 0.001; p = 0.004 and p = 0.000, respectively). Neither intra-vaginal radiation therapy of concomitant chemotherapy in addition to pelvic radiation significantly altered ovarian survival. Conclusions Our data shows that ovarian transposition prior to pelvic radiation is effective in women until the age of 35 years and needs to be discussed in patients aged 36–40 years.


    • 1 March 2018
      • Vol. 39  (2) , 147-155

    LEARNING ASPECTS IN IMPLEMENTING A VITRIFICATION PROGRAM USING MOUSE BLASTOCYSTS

    by E. J. Hoekman, K. E. Tucker, C. A. M. Jansen, C. G. Hilders

    BACKGROUND: Oocyte vitrification is important for fertility preservation. There are debates, however, surrounding the components of the procedure itself. OBJECTIVE: before starting a vitrification program, we decided to (1) determine if blastocysts derived from previously frozen mouse embryos would be suitable to practice vitrification and (2) to analyze the factors that contributed to improving our "learning curve". MATERIALS AND METHODS: 58 expanded blastocysts cultured from commercially available frozen 1-cell mouse embryos (B6D2F1 x B6C3F1) were used. Embryos were vitrified, during 2 separate attempts, in a closed device (Cryopette) and vitrified and warmed using Ethylene Glycol-cryoprotectant vitrification kit (Vitrification Attempt 1 and 2 - VA1 and 2; Warming Attempt 1 and 2 - WA1 and 2). Differences in attempts by more focusing on the reaction of the embryo itself. The survival rate (SR) of embryos was evaluated immediately after warming (TO), then rinsed and cultured for 24 hours in an HTF-like medium (Cleavage Medium - Sage; Cooper Surgical; U.S.A.). Additional evaluations were done at 2 and 24 hours of culture (T2 and T24, respectively). RESULTS: The combined SR for both attempts were 70.6, 60.3 and 34.4% at TO, T2 and T24, respectively. Embryo loss was significantly higher in WA1 compared to WA2 (30.8 versus 10.1%; p=.05). The SR at TO after VA1 and VA2 were similar (90.9 versus 80.9%) and the SR after VA1+WA1 versus VA1+WA2 was 55.6 vs. 76.9% at T2 and 22.2 vs. 61.5% at T24, respectively (NS). CONCLUSION: Commercially frozen mouse embryos can provide essential information for initiating a Vitrification Program applicable to human embryos and oocytes. Practice is critical, particularly Warming, which can provide the confidence needed to adapt and optimize these protocols before vitrifying limited human tissues or gametes.

  • Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach

    by Ellen J. Hoekman, Vincent T.H.B.M. Smit, Timothy P. Fleming, Leonie A. Louwe, Gert Jan Fleuren, Carina G.J.M. Hilders